A5037165641- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- T-cell and Retrovirus Studies
- Hematological disorders and diagnostics
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Thermal Regulation in Medicine
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Autoimmune and Inflammatory Disorders Research
- Inflammatory Bowel Disease
- Viral-associated cancers and disorders
- Microscopic Colitis
- Viral Infections and Vectors
- Bone and Joint Diseases
- Autoimmune and Inflammatory Disorders
Huadong Hospital
2018-2024
Fudan University
2018-2024
Abstract Background The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge, especially in the elderly. Methods A total 83 patients (median age 65 years), who have achieved complete response after induction therapy, were divided into two groups: R 2 + GM‐CSF regimen (lenalidomide, rituximab, granulocyte‐macrophage colony‐stimulating factor [GM‐CSF]) as maintenance therapy ( n = 39) and observation 44). efficacy patient with BCL was analyzed compared observation. Results number...
This study was aimed at comparing the efficacy and tolerability of an arsenic trioxide/bortezomib/ascorbic acid/dexamethasone (ABCD) regimen with a bortezomib/dexamethasone (BD) in patients newly diagnosed myeloma.Fifty-seven sixty-four were treated ABCD BD regimens, respectively. Eligible agreeable received autologous hematopoietic stem cell transplantation followed by consolidation.The response rates (above VGPR) 74.1% 32.8% ABCD- BD-treated groups, respectively (P = 0.000). Compared to...
Background/Aims: Ulcerative colitis (UC) is an incurable, relapsing-remitting inflammatory disease that increases steadily.Mucosal healing has become the primary therapeutic objective for UC.Nevertheless, endoscopic assessments are invasive, expensive, time-consuming, and inconvenient.Therefore, it crucial to develop a noninvasive predictive model monitor activity in patients with UC.Methods: Clinical data of 198 adult UC were collected from January 2016 August 2022 at Huadong Hospital,...
Background There was little evidence of autologous stem cell transplantation (ASCT) as consolidation therapy after remission induction for patients with Peripheral T-cell lymphoma (PTCL). In this study, we conducted a comparative analysis real-world survival outcomes between and observation in PTCL. Methods A total 92 peripheral (PTCL) who were admitted to the Department Hematology, Huadong Hospital Affiliated Fudan University from January 2013 April 2019 divided into two groups based on...
Peripheral T-cell lymphomas (PTCL) frequently result in relapsed or refractory diseases. Upfront autologous hematopoietic stem cell transplantation (ASCT) using the BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen is recommended. However, relapses are common PTCL, highlighting a critical need for improved survival outcomes these patients.
Abstract BackgroundLymphoma is found to be the main source of non-infectious fever unknown origin (FUO). However, there a lack clinical features and outcomes in lymphoma patients initially presenting as FUO.MethodsFrom January 1, 2013 December 31, 2019, our center enrolled 185 who presented FUO then confirmed Huadong Hospital Fudan University. During same study period, 332 without received treatment center. After exclusion, 509 were included retrospectively study. The differences...
The use of immunomodulators represented by thalidomide and its derivatives in the treatment multiple myeloma (MM) has made a breakthrough. Cereblon been identified as direct target for plays significant role antiproliferation, proapoptotic effects, antiangiogenic activities, enhancement activity T cells NK intervention cell surface adhesion molecules between bone marrow stromal cells. In recent years, majority MM patients treated with develop drug resistance. Both upstream downstream factor...
Abstract Background The clinical outcome of B-cell lymphoma has improved dramatically due to hematopoietic stem cell transplantation (HSCT) and biological agents. However, treatment high-risk B in the elderly remains a challenge because their ineligibility for HSCT, high mortality relapse rates. Maintenance therapy improve prognosis might be feasible. Methods We analyzed efficacy combination human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) with R2 regimen...
Abstract Background The clinical outcome of B-cell lymphoma has improved dramatically due to hematopoietic stem cell transplantation (HSCT) and biological agents. However, treatment high-risk B in the elderly remains a challenge because their ineligibility for HSCT, high mortality relapse rates. Maintenance therapy improve prognosis might be feasible. Methods We analyzed efficacy combination human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) with R2 regimen...
Abstract Background: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) remains controversial as a front-line therapy for high-risk diffuse large B lymphoma (DLBCL). Moreover, whether modifying the conditioning regimen with anthracyclines DLBCL will improve effect and achieve deeper response in upfront HSCT unexplored. Methods: In present study, we retrospectively compared outcomes of 156 patients treated non-HSCT, or salvage consisting mitoxantrone,...